アメリカの全身麻酔薬市場(~2025年):投与経路別(静脈内、吸入)、エンドユーザー別(病院、外来手術センター)

◆英語タイトル:US General Anesthesia Drugs Market by Route of Administration (Intravenous and Inhalational), End User (Hospitals, Ambulatory Surgery Centers) - Forecast to 2025
◆商品コード:PH1174
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年2月20日
◆ページ数:117
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アメリカ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社はアメリカの全身麻酔薬市場規模が2020年20億ドルから2025年24億ドルまで、年平均3.4%成長すると予想しています。本調査レポートでは、全身麻酔薬のアメリカ市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、流通構造、主要情報、製品分析、エンドユーザー別(病院、外来手術センター)分析、競争状況、企業評価、企業情報などをまとめております。
【レポートの概要】

“The US general anesthesia drugs market size is projected to reach USD 2.4 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 3.4% during the forecast period.”The major factors driving the growth of this market are the rapid growth in geriatric population, rising prevalence of cancer and increasing number of emergency surgeries. However, issues related to the side effects of general anesthesia drugs in pregnant women and children are likely to restrain the market growth to a certain extent.

“By route of administration, the intravenous drugs accounted for the largest share of the US general anesthesia drugs market.”
The intravenous drugs segment is expected to account for the largest market share in 2020. Factors such rapid onset of action, introduction of new anesthesia drugs with desired pharmacologic effects is expected to drive the market of intravenous anesthesia drugs. Moreover, intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment. Among intravenous anesthesia drugs, propofol accounted for the major share of the market in 2020. Smooth onset of action, high rate of total body clearance and less side effects are some of the factors contributing to high uptake of propofol as an anesthetic agent.

“By End user, Hospitals accounted for the largest share of the US general anesthesia drugs market”
The hospitals segment accounted for the largest share of the US general anesthesia drugs market in 2019. The massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities are the factors responsible for the largest share of the segment.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers – 55%

The US general anesthesia drugs market is dominated by a few established players such as Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada).

Research Coverage:
The report segments the US general anesthesia drugs market based on route of administration ((inhalational (sevoflurane, desflurane, isoflurane and nitrous oxide) and intravenous (propofol, benzodiazepines, ketamine, methohexital sodium and others)),end user (hospitals and ambulatory surgery centers). Company type (Tier 1, tier 2, Tier 3 providers of general anesthesia drugs). The report also provides a comprehensive review of market drivers, challenges, and opportunities in the US general anesthesia drugs market.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the US general anesthesia drugs market and provides them information on key market drivers, challenges, and opportunities.

【レポートの目次】

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
1.7 SUMMARY OF CHANGES 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 19
2.1.2 PRIMARY DATA 20
FIGURE 1 BREAKDOWN OF PRIMARIES: US GENERAL ANESTHESIA DRUGS MARKET 20
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 21
FIGURE 2 DATA TRIANGULATION METHODOLOGY 21
2.2 MARKET ESTIMATION METHODOLOGY 22
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION) 22
FIGURE 4 US GENERAL ANESTHESIA DRUGS MARKET SIZE (USD MILLION) 22
FIGURE 5 US GENERAL ANESTHESIA DRUGS MARKET: GROWTH RATE OF TOP COMPANIES (2018−2019) 23
FIGURE 6 US GENERAL ANESTHESIA DRUGS MARKET: FINAL
CAGR PROJECTIONS (2020−2025) 23
2.3 INDUSTRY INSIGHTS 24
2.4 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
FIGURE 7 US GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD MILLION) 25
FIGURE 8 US GENERAL ANESTHESIA DRUGS MARKET FOR INTRAVENOUS GENERAL ANESTHETICS, BY TYPE, 2020 VS. 2025 (USD MILLION) 26
FIGURE 9 US GENERAL ANESTHESIA DRUGS MARKET FOR INHALATIONAL GENERAL ANESTHETICS, BY TYPE, 2020 VS. 2025 (USD MILLION) 27
4 PREMIUM INSIGHTS 28
4.1 US GENERAL ANESTHESIA DRUGS MARKET OVERVIEW 28
FIGURE 10 INCREASING NUMBER OF EMERGENCY SURGERIES AND THE RAPIDLY GROWING AGING POPULATION TO DRIVE MARKET GROWTH 28
4.2 US GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2020 VS. 2025 29
FIGURE 11 HOSPITALS HOLD THE LARGEST SHARE OF THE US GENERAL ANESTHESIA DRUGS MARKET 29
5 MARKET OVERVIEW 30
5.1 MARKET ANALYSIS 30
5.2 MARKET DYNAMICS 30
FIGURE 12 US GENERAL ANESTHESIA DRUGS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 30
5.2.1 DRIVERS 31
5.2.1.1 Rapid growth in the geriatric population 31
5.2.1.2 Rising prevalence of cancer 31
5.2.1.3 Rising number of emergency surgeries 31
5.2.2 RESTRAINTS 32
5.2.2.1 Risks associated with general anesthesia in pediatric patients and pregnant women 32
TABLE 1 LIST OF GENERAL ANESTHETICS AND SEDATION DRUGS AFFECTED BY LABEL CHANGE 32
5.2.3 OPPORTUNITIES 33
5.2.3.1 Patent expiry of Lusedra 33
5.3 MARKET SIZE 33
5.3.1 HISTORICAL MARKET TRENDS, 2016–2019 33
FIGURE 13 US KETAMINE MARKET, 2016–2019 (USD MILLION) 33
5.3.2 MARKET FORECASTS, 2020–2025 34
FIGURE 14 US KETAMINE MARKET, 2020–2025 (USD MILLION) 34
5.4 IMPACT OF COVID-19 ON THE GROWTH OF THE US GENERAL ANESTHESIA DRUGS MARKET 34
6 DISTRIBUTION STRUCTURE 35
6.1 US KETAMINE MARKET: DISTRIBUTION STRUCTURE 35
FIGURE 15 DISTRIBUTION STRUCTURE 36
TABLE 2 US: KETAMINE MARKET, BY DISTRIBUTION CHANNEL,
2016–2019 (USD MILLION) 36
TABLE 3 US: KETAMINE MARKET, BY DISTRIBUTION CHANNEL,
2020–2025 (USD MILLION) 37
6.1.1 US KETAMINE MARKET, BY MANUFACTURER 37
TABLE 4 US: KETAMINE MARKET, BY MANUFACTURER, 2016–2019 (USD MILLION) 37
TABLE 5 US: KETAMINE MARKET, BY MANUFACTURER, 2016–2019 (KILOGRAM) 38
TABLE 6 US: KETAMINE MARKET, BY MANUFACTURER, 2020–2025 (USD MILLION) 38
TABLE 7 US: KETAMINE MARKET, BY MANUFACTURER, 2020–2025 (KILOGRAM) 38
6.1.2 US KETAMINE MARKET, BY DISTRIBUTION CHANNEL 39
6.1.2.1 Group purchasing organizations 39
FIGURE 16 US KETAMINE MARKET SHARE, BY GPO (2019) 39
TABLE 8 US: KETAMINE MARKET, BY GPO, 2016–2019 (USD MILLION) 39
TABLE 9 US: KETAMINE MARKET, BY GPO, 2016–2019 (KILOGRAM) 40
TABLE 10 US: KETAMINE MARKET, BY GPO, 2020–2025 (USD MILLION) 40
TABLE 11 US: KETAMINE MARKET, BY GPO, 2020–2025 (KILOGRAM) 40
6.1.2.2 Distributors 41
FIGURE 17 US KETAMINE MARKET SHARE, BY DISTRIBUTOR (2019) 41
TABLE 12 US: KETAMINE MARKET, BY DISTRIBUTOR, 2016–2019 (USD MILLION) 41
TABLE 13 US: KETAMINE MARKET, BY DISTRIBUTOR, 2016–2019 (KILOGRAM) 42
TABLE 14 US: KETAMINE MARKET, BY DISTRIBUTOR, 2020–2025 (USD MILLION) 42
TABLE 15 US: KETAMINE MARKET, BY DISTRIBUTOR, 2020–2025 (KILOGRAM) 42
6.2 KEY LEGAL TRENDS FOR CONTROLLED SUBSTANCES 43
6.2.1 COMPLIANCE ASSOCIATED WITH THE MANUFACTURING OF
NARCOTICS IN THE US 43
6.2.1.1 Registration 43
6.2.1.2 Security 43
6.2.1.3 Labeling and packaging 43
6.2.1.4 Inventory 43
6.2.1.5 Records 43
6.2.2 COMPLIANCE ASSOCIATED WITH VENDORS OF NARCOTICS IN THE US 44
6.3 PRODUCT CATEGORY ENUMERATION 44
6.3.1 KETAMINE 44
6.3.2 OTHER BRANDS 44
7 US GENERAL ANESTHESIA DRUGS MARKET: KEY INFORMATION 46
7.1 IMPORT & EXPORT SYSTEMS IN THE US 46
7.1.1 IMPORT OF CONTROLLED SUBSTANCES 46
7.1.1.1 Shipment of controlled substances 46
7.1.1.2 Registration of applicants for the import and export of controlled substances 46
7.1.2 EXPORT OF CONTROLLED SUBSTANCES 47
7.1.2.1 Exceptions in exportation for special scientific purposes 48
7.1.2.2 Custom tariffs for imports 48
TABLE 16 HARMONIZED TARIFF SCHEDULE FOR ANESTHESIA DRUGS 48
TABLE 17 ANESTHESIA MOLECULES: CHEMICAL ABSTRACTS SERVICES NUMBERS 49
7.1.3 TRANSPORT OF CONTROLLED SUBSTANCES 49
7.1.4 CUSTOMS CLEARANCE 49
FIGURE 18 CUSTOMS CLEARANCE PROCEDURE FOR IMPORTED CONTROLLED SUBSTANCES IN THE US 51
FIGURE 19 EXPORT CUSTOMS CLEARANCE PROCEDURE FOR CONTROLLED SUBSTANCES IN THE US 53
7.1.5 NON-TARIFF BARRIERS 54
TABLE 18 REGULATORY REQUIREMENTS FOR CONTROLLED SUBSTANCES 55
7.2 TOP RELATED EXHIBITIONS 56
TABLE 19 ANESTHESIA EXHIBITIONS/WORKSHOPS/CONFERENCES IN THE US 56
7.3 DESCRIPTION OF POTENTIAL BUYERS 56
TABLE 20 POTENTIAL GROUP PURCHASING ORGANIZATIONS 56
TABLE 21 POTENTIAL DISTRIBUTORS 57
FIGURE 20 BUSINESS STRATEGY 58
8 PRODUCT ANALYSIS 60
8.1 ANESTHESIA DRUGS MARKET SEGMENTATION IN THE US 61
FIGURE 21 ANESTHESIA DRUGS MARKET SEGMENTATION 61
FIGURE 22 LOCATION QUOTIENT OF ANESTHESIA SPECIALISTS IN THE US,
BY STATE (MAY 2019) 62
FIGURE 23 ANESTHESIA LANDSCAPE 62
TABLE 22 ANESTHESIA DRUGS MARKET, BY TYPE, 2016–2019 (USD MILLION) 63
TABLE 23 ANESTHESIA DRUGS MARKET, BY TYPE, 2020–2025 (USD MILLION) 63
8.2 GENERAL ANESTHESIA 63
8.2.1 INTRODUCTION 63
8.2.2 GENERAL ANESTHESIA DRUGS MARKET SEGMENTATION 64
FIGURE 24 SEGMENTATION OF THE GENERAL ANESTHESIA DRUGS MARKET 64
TABLE 24 US: GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2016–2019 (USD MILLION) 64
TABLE 25 US: GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 65
8.3 INTRAVENOUS GENERAL ANESTHETICS 65
TABLE 26 US: INTRAVENOUS GENERAL ANESTHETICS MARKET, BY TYPE,
2016–2019 (USD MILLION) 65
TABLE 27 US: INTRAVENOUS GENERAL ANESTHETICS MARKET, BY TYPE,
2020–2025 (USD MILLION) 66
8.4 INHALATIONAL GENERAL ANESTHETICS 66
TABLE 28 US: INHALATIONAL GENERAL ANESTHETICS MARKET, BY TYPE,
2016–2019 (USD MILLION) 66
TABLE 29 US: INHALATIONAL GENERAL ANESTHETICS MARKET, BY TYPE,
2020–2025 (USD MILLION) 67
8.4.1 MAJOR BRANDS/MOLECULES 67
8.4.1.1 Propofol 67
8.4.1.2 Benzodiazepines 67
8.4.1.3 Methohexital Sodium 68
8.5 COMPETITION IN THE US 68
FIGURE 25 PROPERTIES OF INTRAVENOUS ANESTHESIA DRUGS 68
FIGURE 26 INTRAVENOUS GENERAL ANESTHETICS MARKET, BY MOLECULE,
2019 (USD MILLION) 69
8.5.1 SALES PRICE 69
TABLE 30 PROPOFOL PRICE, 2020 (USD) 69
TABLE 31 MIDAZOLAM PRICE, 2020 (USD) 70
TABLE 32 METHOHEXITAL SODIUM PRICE, 2020 (USD) 70
TABLE 33 ETOMIDATE PRICE, 2020 (USD) 71
TABLE 34 KETAMINE PRICE, 2020 (USD) 71
8.5.2 MAJOR BRANDS 72
TABLE 35 GENERAL INTRAVENOUS ANESTHESIA DRUGS: USAGE TRENDS 72
8.6 POTENTIAL BUYERS IN THE US 72
8.6.1 POTENTIAL BUYERS, BY STATE 72
TABLE 36 GROUP PURCHASING ORGANIZATIONS, BY STATE 72
TABLE 37 DISTRIBUTORS, BY STATE 73
9 US GENERAL ANESTHESIA DRUGS MARKET, BY END USER 74
9.1 INTRODUCTION 75
TABLE 38 US: GENERAL ANESTHESIA DRUGS MARKET, BY END USER,
2016–2019 (USD MILLION) 75
TABLE 39 US: GENERAL ANESTHESIA DRUGS MARKET, BY END USER,
2020–2025 (USD MILLION) 75
9.1.1 HOSPITALS 75
9.1.1.1 Growing patient pool in hospitals to drive market growth 75
9.1.2 AMBULATORY SURGERY CENTERS 76
9.1.2.1 Increasing number of ASCs in the country to boost the market growth 76
10 COMPETITIVE LANDSCAPE 77
10.1 OVERVIEW 77
10.2 MARKET SHARE ANALYSIS (2019) 77
FIGURE 27 US GENERAL ANESTHESIA DRUGS MARKET SHARE, BY KEY PLAYER, 2019 77
10.3 KEY MARKET DEVELOPMENTS 78
10.3.1 PRODUCT LAUNCHES 78
10.3.2 ACQUISITIONS 79
10.3.3 EXPANSIONS 79
10.3.4 PARTNERSHIPS 79
11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 80
11.1 OVERVIEW 80
11.2 COMPETITIVE LEADERSHIP MAPPING: MAJOR MARKET PLAYERS (2019) 80
11.2.1 STARS 80
11.2.2 EMERGING LEADERS 80
11.2.3 PERVASIVE PLAYERS 81
11.2.4 PARTICIPANTS 81
FIGURE 28 US GENERAL ANESTHESIA DRUGS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 81
12 COMPANY PROFILES 82
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 PFIZER, INC. 82
FIGURE 29 PFIZER, INC.: COMPANY SNAPSHOT (2019) 82
12.2 FRESENIUS SE & CO. KGAA 84
FIGURE 30 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2019) 84
12.3 BAXTER INTERNATIONAL INC. 86
FIGURE 31 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT (2019) 86
12.4 HIKMA PHARMACEUTICALS PLC 88
FIGURE 32 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019) 88
12.5 ABBVIE 90
FIGURE 33 ABBVIE: COMPANY SNAPSHOT (2019) 90
12.6 PIRAMAL ENTERPRISES LIMITED 92
FIGURE 34 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2020) 92
12.7 ABBOTT LABORATORIES 94
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 94
12.8 ASTRAZENECA PLC 95
FIGURE 36 ASTRAZENECA PLC: COMPANY SNAPSHOT (2019) 95
12.9 NOVARTIS AG 96
FIGURE 37 NOVARTIS AG: COMPANY SNAPSHOT (2019) 96
12.10 F. HOFFMANN-LA ROCHE LTD. 98
FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019) 98
12.11 BAYER AG 100
FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2019) 100
12.12 GLAXOSMITHKLINE PLC 102
FIGURE 40 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019) 102
12.13 GILEAD SCIENCES 104
FIGURE 41 GILEAD SCIENCES: COMPANY SNAPSHOT (2019) 104
12.14 MERCK & CO., INC. 105
FIGURE 42 MERCK & CO., INC.: COMPANY SNAPSHOT (2019) 105
12.15 SANOFI 106
FIGURE 43 SANOFI: COMPANY SNAPSHOT (2019) 106
12.16 PAR PHARMACEUTICAL 108
12.17 TEVA PHARMACEUTICALS 108
12.18 VIATRIS (MYLAN) 109
12.19 HERITAGE PHARMACEUTICALS INC. 109
12.20 AKORN 110
12.21 APOTEX 111
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 112
13.1 DISCUSSION GUIDE 112
13.2 KNOWLEDGE STORE 115
13.3 RELATED REPORTS 117
13.4 AUTHOR DETAILS 118



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アメリカの全身麻酔薬市場(~2025年):投与経路別(静脈内、吸入)、エンドユーザー別(病院、外来手術センター)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆